Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $54.7 million.

  • 4D Molecular Therapeutics' Total Non-Current Liabilities rose 7.83% to $54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.7 million, marking a year-over-year increase of 7.83%. This contributed to the annual value of $49.4 million for FY2024, which is 55.77% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Total Non-Current Liabilities stood at $54.7 million, which was up 4.28% from $52.4 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Total Non-Current Liabilities ranged from a high of $54.7 million in Q3 2025 and a low of $12.4 million during Q2 2021.
  • For the 3-year period, 4D Molecular Therapeutics' Total Non-Current Liabilities averaged around $39.0 million, with its median value being $31.7 million (2023).
  • Per our database at Business Quant, 4D Molecular Therapeutics' Total Non-Current Liabilities surged by 143.15% in 2022 and then dropped by 12.05% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $34.2 million in 2021, then dropped by 11.32% to $30.3 million in 2022, then climbed by 4.61% to $31.7 million in 2023, then spiked by 55.77% to $49.4 million in 2024, then rose by 7.83% to $54.7 million in 2025.
  • Its Total Non-Current Liabilities was $54.7 million in Q3 2025, compared to $52.4 million in Q2 2025 and $45.7 million in Q1 2025.